US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
Omvoh is now approved in the United States for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults. Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. Lilly says that Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval.
The FDA decision was based on positive results from the Phase 3 VIVID-1 study of Omvoh in adults with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine and methotrexate) and/or biologics (TNF blockers, integrin receptor antagonists).
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval